Cancer treatment: Role of natural products. Time to have a serious rethink

Mali, Shrikant B.

doi:10.1016/j.oor.2023.100040

Cited by 10 publications

(6 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extensive research indicates that various natural products can therapeutically influence NSCLC by modulating autophagy and apoptosis ( 21 , 158 , 159 ). Natural products such as camptothecin, vincristine and paclitaxel have been successfully used in clinical applications, and the search for active ingredients with anti-tumor activity and low toxicity from natural products has become a hot research topic for researchers in recent years.…”

Section: Effects Of Four Natural Products Regulating Autophagy and Ap...mentioning

confidence: 99%

Natural products targeting autophagy and apoptosis in NSCLC: a novel therapeutic strategy

Qin,

Li,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) being the predominant type. The roles of autophagy and apoptosis in NSCLC present a dual and intricate nature. Additionally, autophagy and apoptosis interconnect through diverse crosstalk molecules. Owing to their multitargeting nature, safety, and efficacy, natural products have emerged as principal sources for NSCLC therapeutic candidates. This review begins with an exploration of the mechanisms of autophagy and apoptosis, proceeds to examine the crosstalk molecules between these processes, and outlines their implications and interactions in NSCLC. Finally, the paper reviews natural products that have been intensively studied against NSCLC targeting autophagy and apoptosis, and summarizes in detail the four most retrieved representative drugs. This paper clarifies good therapeutic effects of natural products in NSCLC by targeting autophagy and apoptosis and aims to promote greater consideration by researchers of natural products as candidates for anti-NSCLC drug discovery.

show abstract

Section: Effects Of Four Natural Products Regulating Autophagy and Ap...mentioning

confidence: 99%

Natural products targeting autophagy and apoptosis in NSCLC: a novel therapeutic strategy

Qin,

Li,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Using natural products in medicine has also been a well-known strategy in drug discovery. Examples of common natural products in cancer treatment are taxanes, vinca alkaloids and anthracyclines [33]. Quercetin is a flavonoid found in most fruits and vegetables, possibly one of the most common dietary flavonols [34].…”

Section: Preclinical Therapeutic Effects and Associated Molecular Mec...mentioning

confidence: 99%

Preclinical Therapeutic Effects of Quercetin on Gastrointestinal Cancers

Xin Jie Tune,

Seng Wu,

Mac Guad

et al. 2024

Quercetin - Effects on Human Health [Working Title]

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers were included in the top 10 most common cancers in 2020. Future incidences are expected to rise due to the varying risk factors and aetiologies. With high incidences and mortality rates, current cancer treatments fail to reduce mortality and morbidity in GI cancer patients. A large part of cancer research has been geared towards targeted and personalized medicine, although effective, it may not be the most cost-friendly and feasible option to treat patients from varying socioeconomic backgrounds. Hence, natural compounds may present as an attractive alternative treatment in the management of GI cancers. Quercetin is a well-known flavonoid compound, found in almost all fruits and vegetables. It has also been widely studied for its anticancer properties, such as anti-oxidative, anti-inflammatory, anti-proliferative and anti-angiogenic properties. In this chapter, the authors discuss the potential of quercetin in treating GI cancers, which includes the biosafety and toxicity of quercetin, applications of quercetin in common GI cancers, such as gastric, hepatic, colorectal, pancreatic and oesophageal cancers, along with the corresponding molecular mechanisms. The authors also present evidences of quercetin as an adjuvant therapeutic agent with other anticancer drugs.

show abstract

“…20 In the case of CDK5, this is a bulky Phe80, however, in a multiple kinase screening of known type-II inhibitors against more than 442 kinases, some CDK5 inhibition was observed for certain compounds (Figure 1), suggesting the potential for pursuing this approach. 21 The contribution of natural products to drug discovery has been recognized for many decades, particularly in the area of cancer, 22,23 providing optimism for also achieving success against GBM. In this study, Desmond metadynamics (MetaD) and molecular dynamics (MD) simulations were used to predict a CDK5 DFG-out model that allowed in silico screening for type-II inhibitors, using molecular docking of natural product based compounds (ZINC15 biogenic database).…”

Section: Introductionmentioning

confidence: 99%

“…The contribution of natural products to drug discovery has been recognized for many decades, particularly in the area of cancer, , providing optimism for also achieving success against GBM. In this study, Desmond metadynamics (MetaD) and molecular dynamics (MD) simulations were used to predict a CDK5 DFG-out model that allowed in silico screening for type-II inhibitors, using molecular docking of natural product based compounds (ZINC15 biogenic database) .…”

Section: Introductionmentioning

confidence: 99%

Discovery of Potent Multikinase Type-II Inhibitors Targeting CDK5 in the DFG-out Inactive State with Promising Potential against Glioblastoma

Khan,

Welsby,

Stasik

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

Kinases have proven valuable targets in successful cancer drug discovery projects, but not yet for malignant brain tumors where type-II inhibition of cyclin-dependent kinase 5 (CDK5) stabilizing the DFG-out inactive state has potential for design of selective and clinically efficient drug candidates. In the absence of crystallographic evidence for a CDK5 DFG-out inactive state protein−ligand complex, for the first time, a model was designed using metadynamics/molecular dynamics simulations. Glide docking of the ZINC15 biogenic database identified [pyrimidin-2-yl]amino-furo[3,2-b]-furyl-urea/amide hit chemical scaffolds. For four selected analogues (4, 27, 36, and 42), potent effects on glioblastoma cell viability in U87-MG, T98G, and U251-MG cell lines and patient-derived cultures were generally observed (IC 50 s ∼ 10−40 μM at 72 h). Selectivity profiling against 11 homologous kinases revealed multikinase inhibition (CDK2, CDK5, CDK9, and GSK-3α/β), most potent for GSK-3α in the nanomolar range (IC 50 s ∼ 0.23−0.98 μM). These compounds may therefore have diverse anticancer mechanisms of action and are of considerable interest for lead optimization.

show abstract

Cancer treatment: Role of natural products. Time to have a serious rethink

Cited by 10 publications

References 54 publications

Natural products targeting autophagy and apoptosis in NSCLC: a novel therapeutic strategy

Natural products targeting autophagy and apoptosis in NSCLC: a novel therapeutic strategy

Preclinical Therapeutic Effects of Quercetin on Gastrointestinal Cancers

Discovery of Potent Multikinase Type-II Inhibitors Targeting CDK5 in the DFG-out Inactive State with Promising Potential against Glioblastoma

Contact Info

Product

Resources

About